Exhibiting at VIV Asia 2025

Delos Medica

Delos Medica, headquartered in Otopeni, Romania, is a leading veterinary pharmaceutical manufacturer, specializing in high-quality medicated feed premixes, injectable solutions, and oral treatments for livestock and companion animals. With a strong focus on research and innovation, Delos Medica is committed to improving animal health and performance through scientifically formulated veterinary medicines.

Core Business and Specialization

Delos Medica is at the forefront of veterinary pharmaceuticals and animal health solutions, offering a wide range of medicated treatments and feed additives designed for livestock, poultry, and aquaculture. The company's core expertise includes:

• Antibiotic and Antibacterial Treatments – Developing targeted solutions to combat bacterial infections in farm animals.
• Injectable and Oral Solutions – High-potency injectable antibiotics and oral suspensions for rapid disease control.
• Medicated Feed Additives – Premixes designed to enhance feed efficiency and prevent infections.
• Sustainable Animal Health Solutions – A commitment to reducing antibiotic resistance through responsible veterinary practices.

Product and Service Offerings

Delos Medica provides a comprehensive range of veterinary medicines, categorized into three major segments:

1. Oral Solutions

• Bromex – A broad-spectrum antimicrobial solution for bacterial infections in poultry and swine.
• Florfenidem 10% – A florfenicol-based oral antibiotic, effective against respiratory and gastrointestinal infections.
• Tilmicodem 25 – A tilmicosin-based macrolide antibiotic for controlling respiratory diseases in livestock.

2. Injectable Solutions

• Lincodem – A lincomycin injectable solution, commonly used in swine and poultry for bacterial infections.
• Florfenidem – A highly bioavailable injectable antibiotic for swine, cattle, and poultry diseases.

3. Medicated Feed Premixes

• Colidem 10% – A colistin sulfate-based feed additive for treating intestinal infections in livestock.
• Tiadem 10% – A tylosin-based premix used in feed to enhance growth and disease resistance.

Market Reach and Export Performance

Delos Medica has a strong market presence in Europe, Asia, and the Middle East, with an expanding distribution network in Latin America and Africa.

• Annual sales growth of 18%, reflecting increasing demand for high-quality veterinary pharmaceuticals.
• Exporting to more than 30 countries, with strategic partnerships in the global livestock industry.
• Over 1,500 veterinary clinics, farms, and feed mills incorporate Delos Medica products in livestock healthcare programs.

Financial Strength and Growth

Delos Medica has demonstrated consistent financial growth, driven by expansion in manufacturing capacity and new product development.

• Annual revenue: $120 million USD (2023).
• Investment in R&D accounts for 12% of total revenue, ensuring continuous product innovation.
• Expansion of manufacturing facilities by 20% in the past three years, supporting higher production volumes and global demand.

Certifications and Compliance

Delos Medica adheres to strict international regulatory and safety standards, ensuring quality, efficacy, and compliance across all veterinary products. The company holds:

• Good Manufacturing Practices (GMP) Certification – Ensuring pharmaceutical-grade veterinary drug production.
• ISO 9001 – Certified quality management system.
• HACCP Compliance – Guaranteeing biosecurity and safety in animal health products.
• European Union Veterinary Drug Certification – Meeting EU standards for animal pharmaceuticals.
• World Organization for Animal Health (OIE) Compliance – Supporting responsible antibiotic use in veterinary medicine.

Research and Innovation

Delos Medica operates state-of-the-art research and development facilities, focusing on antimicrobial resistance, precision medicine, and next-generation animal health solutions.

• Collaboration with leading European veterinary research institutes to advance disease prevention and treatment.
• Development of innovative formulations to improve drug bioavailability and efficacy.
• Investment in alternative therapies, including probiotics and immune-boosting supplements.

Customer Testimonials

Delos Medica has received strong recognition from veterinarians, livestock producers, and feed manufacturers:

• "Florfenidem 10% has significantly improved the health and survival rate of our poultry flocks." – Poultry Farm Manager, Spain.
• "The efficiency of Tilmicodem 25 in treating respiratory diseases has helped us reduce mortality rates in our swine herds." – Swine Veterinarian, Germany.
• "Colidem 10% has enhanced gut health and performance in our cattle, lowering treatment costs." – Livestock Producer, Saudi Arabia.

Major Achievements

• Ranked among the Top 10 Veterinary Pharmaceutical Manufacturers in Europe.
• Winner of the Veterinary Innovation Award 2023 for advancements in injectable antibiotic technology.
• Expansion of export markets to Latin America and Africa, reinforcing its global leadership in veterinary medicine.
• Patented new formulation techniques, improving drug stability and absorption rates.

Delos Medica continues to redefine veterinary medicine, delivering science-driven, high-performance pharmaceutical solutions that support sustainable and profitable livestock farming worldwide.